An Overview of a Practice-Changing Trial With mFOLFIRINOX in Pancreatic Cancer
Thierry Conroy, MD, a medical oncologist and director at the Institut de Cancerologie de Lorraine in Nancy, France, shares some background on the PRODIGE 24/CCTG PA.6 trial where a modified FOLFIRINOX regimen was found superior to the adjuvant standard of care, gemcitabine, in patients with resected pancreatic cancer.
Thierry Conroy, MD, a medical oncologist and director at the Institut de Cancerologie de Lorraine in Nancy, France, shares some background on the PRODIGE 24/CCTG PA.6 trial where a modified FOLFIRINOX (mFOLFIRINOX) regimen was found superior to the adjuvant standard of care, gemcitabine, in patients with resected pancreatic cancer.
While gemcitabine has been the standard of care since 2008, a mFOLFIRINOX regimen of fluorouracil (5-FU), oxaliplatin, leucovorin, and irinotecan was developed in France to show superiority. While it was superior to gemcitabine in metastatic disease, it was still too toxic for use in the adjuvant setting.
Bolus 5-FU is suppressed in the mFOLFIRINOX regimen and instead continuous infusion of 5-FU is used with the other agents. In this trial, mFOLFIRINOX was compared to gemcitabine in patients 3 to 12 weeks after surgery for 6 months.
See more information on thispractice-changing trial in pancreatic cancer and the results
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
April 10th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.
Read More
